# GH Research (GHRS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/GHRS
## Company Profile
- Ticker: GHRS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Ireland and listed in the U
- Tags: CNS
## Stock Data
- Close: 29.13 USD
- Market cap: 1706303815.53 USD
- Last updated: 2026-08-05
## Business Overview
### Neuropsychiatric Therapeutics Company
GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders.
### GH001
GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals across patients with differing numbers of prior treatment failures.
### Delivery and Development Platform
The company is using dedicated inhalation technology and controlled clinical administration to develop short-duration treatments with potentially durable therapeutic effects.
## Why The Stock Is Moving

The latest monitored company update is “GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- GH Research is seeking FDA alignment on a global Phase 3 pivotal program for GH001 in treatment-resistant depression.
- Initiation of the global pivotal program is targeted for late 2026.

## Drug Assets

- GH001

## Recent News
- 2026-08-06 11:00 EST — [GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GHRS/gh-research-reports-second-quarter-2026-financial-results-and-provides-business--14c0e67c) — Source: GH Research
- 2026-06-04 11:00 EST — [GH Research Announces Publication of Phase 2a Postpartum Depression Results](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results) — Source: GH Research
- 2026-05-14 11:00 EST — [GH Research Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GHRS/gh-research-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: GH Research
- 2026-04-29 12:00 EST — [GH Research Announces Pricing of $117.5 Million Underwritten Offering](https://biopharmsignal.com/news/GHRS/gh-research-announces-pricing-of-117-5-million-underwritten-offering) — Source: GH Research
- 2026-04-20 13:00 EST — [GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness](https://biopharmsignal.com/news/GHRS/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness) — Source: GH Research